ES8601924A1 - Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas. - Google Patents

Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.

Info

Publication number
ES8601924A1
ES8601924A1 ES536499A ES536499A ES8601924A1 ES 8601924 A1 ES8601924 A1 ES 8601924A1 ES 536499 A ES536499 A ES 536499A ES 536499 A ES536499 A ES 536499A ES 8601924 A1 ES8601924 A1 ES 8601924A1
Authority
ES
Spain
Prior art keywords
alkyl
opt
substd
phenylalkyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES536499A
Other languages
English (en)
Other versions
ES536499A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES8601924A1 publication Critical patent/ES8601924A1/es
Publication of ES536499A0 publication Critical patent/ES536499A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Liquid Crystal Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

PROCEDIMIENTO DE PREPARACION DE 2-0-AMINO-5-HIDROXI-4-METILPIRIMIDINAS DE FORMULA (I).CONSISTENTE EN HACER REACCIONAR 5-ACETIL-2-AMINOOXAZOL DE FORMULA (II) CON UNA AMINA RRNH, EN PRESENCIA DE AGUA, A TEMPERATURA COMPRENDIDA ENTRE 90 Y 125º, Y AISLAR EL COMPUESTO DE FORMULA (I) DE LA MEZCLA DE PRODUCTOS RESULTANTE, Y OPCIONALMENTE CONVERTIR EL COMPUESTO DE UNA SAL DE ADICION DE UN ACIDO FARMACEUTICAMENTE ACEPTABLE POR REACCION CON UN ACIDO APROPIADO. R REPRESENTA HIDROGENO O ALQUILO C1-15; Y R HIDROGENO, ALQUILO C1-15, CICLOALQUILO C5-8, ALQUENILO VC2-15, FENILO, FURILO, TIENILO, FENILALQUILO C7-20, O FENILALQUILO SUSTITUIDO POR HALOGENO, ALCOXI O TRIFLUORMETIL. R Y R PUEDEN FORMAR JUNTOS, CON NITROGENO, UN GRUPO PIPERIDILO O PIRROLIDINILO OPCIONALMENTE SUSTITUIDOS. DE APLICACION COMO INHIBIDORES DE LA SINTESIS DE LEUCOTRIENOS, EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES, INFLAMATORIAS, CARDIOVASCULARES, CANCER, PSORIASIS Y ULCERAS PEPTICAS.
ES536499A 1983-10-03 1984-10-03 Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas. Granted ES536499A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/538,233 US4554276A (en) 1983-10-03 1983-10-03 2-Amino-5-hydroxy-4-methylpyrimidine derivatives

Publications (2)

Publication Number Publication Date
ES8601924A1 true ES8601924A1 (es) 1985-11-16
ES536499A0 ES536499A0 (es) 1985-11-16

Family

ID=24146051

Family Applications (1)

Application Number Title Priority Date Filing Date
ES536499A Granted ES536499A0 (es) 1983-10-03 1984-10-03 Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.

Country Status (25)

Country Link
US (1) US4554276A (es)
EP (1) EP0138464B1 (es)
JP (1) JPS6094970A (es)
KR (1) KR860001818B1 (es)
AT (1) ATE47999T1 (es)
AU (1) AU548268B2 (es)
CA (1) CA1215985A (es)
DD (1) DD232698A5 (es)
DE (1) DE3480474D1 (es)
DK (1) DK162222C (es)
EG (1) EG16355A (es)
ES (1) ES536499A0 (es)
FI (1) FI84479C (es)
GR (1) GR80512B (es)
HU (1) HU194186B (es)
IE (1) IE57633B1 (es)
IL (1) IL73104A (es)
NO (1) NO170883C (es)
NZ (1) NZ209740A (es)
PH (1) PH21038A (es)
PL (1) PL148590B1 (es)
PT (1) PT79278B (es)
SU (1) SU1342417A3 (es)
YU (1) YU44058B (es)
ZA (1) ZA847731B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
IE58373B1 (en) * 1986-06-18 1993-09-08 Bloomfield Frederick Jacob 5-Lipoxygenase pathway inhibitors
WO1989000423A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
MX14001A (es) * 1987-12-02 1993-06-01 Pfizer Procedimiento para preparar derivados de hidroxipirimidinas
US4910204A (en) * 1988-06-28 1990-03-20 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
US5071852A (en) * 1988-12-14 1991-12-10 Pfizer Inc. Derivatives of 5-hydroxy and 5-methoxy 2-amino-pyrimidines as inhibitors of interleukin-1 production
ATE96321T1 (de) * 1988-12-14 1993-11-15 Pfizer Derivate von 5-hydroxy- und 5-methoxy-2-aminopyrimidin als inhibitoren der interleukin-1produktion.
US4940712A (en) * 1989-05-26 1990-07-10 Pfizer Inc. Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5248682A (en) * 1991-01-31 1993-09-28 Warner-Lambert Company 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
WO1994001403A1 (en) * 1992-07-08 1994-01-20 Shell Internationale Research Maatschappij B.V. Piperidine derivatives
WO1995024894A2 (en) * 1994-03-14 1995-09-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
WO2002000683A2 (en) * 2000-06-23 2002-01-03 Vanderbilt University Novel chain-breaking antioxidants
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
ATE474559T1 (de) * 2001-06-01 2010-08-15 Pozen Inc Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
DE102004054080A1 (de) * 2004-11-09 2006-05-11 Wella Ag Haut- oder Haarbehandlungsmittel mit Schutzeffekt
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
WO2009089134A1 (en) * 2008-01-04 2009-07-16 Src, Inc. Methods for measuring a patint response upon administration of a drug and compositions thereof
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EP2797600A4 (en) 2011-12-28 2015-09-16 Pozen Inc IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
AU2021310264A1 (en) 2020-07-15 2023-02-09 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
CA3124579A1 (en) 2020-07-15 2022-01-15 Schabar Research Associates Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000138A (en) * 1966-03-31 1976-12-28 Imperial Chemical Industries Limited Organic compounds and compositions containing them
US3932617A (en) * 1974-05-24 1976-01-13 The Upjohn Company Interferon induction
DE2814984A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Pyrimidin(5)yl-(thiono)(thiol)- phosphor(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
IN153791B (es) * 1979-03-10 1984-08-18 Soc D Etudes Prod Chimique
US4416885A (en) * 1979-11-02 1983-11-22 Huve Pierre M Use of isopropylaminopyrimidine in the chemotherapy of muscular dystrophy, myopathy and myotonia
OA07362A (fr) * 1980-10-27 1984-06-30 May & Baker Ltd Dérivés de la pyrimidine, leur procédé de préparation et les compositions les contenant.
US4435396A (en) * 1982-05-10 1984-03-06 Pfizer Inc. Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor

Also Published As

Publication number Publication date
KR860001818B1 (ko) 1986-10-24
GR80512B (en) 1985-02-01
JPS6094970A (ja) 1985-05-28
IE57633B1 (en) 1993-02-10
EG16355A (en) 1987-04-30
FI843864A0 (fi) 1984-10-02
YU44058B (en) 1990-02-28
PL249833A1 (en) 1985-06-04
DK162222B (da) 1991-09-30
PT79278B (en) 1986-11-18
ZA847731B (en) 1986-05-28
PL148590B1 (en) 1989-11-30
EP0138464A2 (en) 1985-04-24
SU1342417A3 (ru) 1987-09-30
FI84479B (fi) 1991-08-30
AU3376884A (en) 1985-04-18
PT79278A (en) 1984-10-01
NO170883C (no) 1992-12-23
DK472184D0 (da) 1984-10-02
NO170883B (no) 1992-09-14
DD232698A5 (de) 1986-02-05
DK162222C (da) 1992-03-02
CA1215985A (en) 1986-12-30
ES536499A0 (es) 1985-11-16
IL73104A (en) 1987-12-20
HU194186B (en) 1988-01-28
YU169584A (en) 1987-02-28
ATE47999T1 (de) 1989-12-15
JPH0528707B2 (es) 1993-04-27
US4554276A (en) 1985-11-19
KR850003402A (ko) 1985-06-17
IL73104A0 (en) 1984-12-31
EP0138464B1 (en) 1989-11-15
DK472184A (da) 1985-04-04
IE842494L (en) 1985-04-03
FI84479C (fi) 1991-12-10
NZ209740A (en) 1987-04-30
FI843864L (fi) 1985-04-04
AU548268B2 (en) 1985-12-05
DE3480474D1 (de) 1989-12-21
NO843968L (no) 1985-04-09
PH21038A (en) 1987-07-03
HUT35651A (en) 1985-07-29
EP0138464A3 (en) 1986-08-20

Similar Documents

Publication Publication Date Title
ES8601924A1 (es) Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas.
ES8601878A1 (es) Procedimiento para preparar nuevas 1-bencil-aminoalquil-pi- rrolidinonas
ES8206523A1 (es) Procedimiento para la obtencion de acidos 7-amino-1-ciclo- propil-4-oxo-1,4-dihidro-naftirin-3-carboxilicos
AU3317495A (en) Aroyl-piperidine derivatives
DE3865112D1 (de) Azolylmethyl-cyclopropyl-derivate.
ES8307218A1 (es) Proceso de fabricacion de los nuevos derivados de la amidinopiperadina.
ES8201116A1 (es) Procedimiento para preparar derivados de 2-nitro-5-(fenoxi sustituido)-benzoilo
ES8604557A1 (es) Un procedimiento para la preparacion de derivados de benzo- tiofeno
ES8601963A1 (es) Un procedimiento para preparar (1h-tetrazol-5-il)-2(1h)-quinolonas
ES8601864A1 (es) Procedimiento para la obtencion de benzoil-ureas.
NO304689B1 (no) Aminoalkylbenzoksazolinoner og benzotiazolinoner
ES463234A1 (es) Procedimiento para preparar compuestos de aril azufre.
ES8602649A1 (es) Procedimiento para preparar 4-hidroximetil-pirrolidinonas substituidas en posicion 1
GB1433571A (en) Esters of 3-4-biphenyl-butan-1-ols and -buten-1-ols
GB1331670A (en) Quaternised benzofuranylbenzimadzoles
ES8704478A1 (es) Procedimiento para la obtencion de derivados de piridina
DE3867563D1 (en) 2-amino-5-hydroxy-4-pyrimidone.
GEP20001939B (en) Alkyl Derivatives of Trazodone with CNS Activity
ES8605269A1 (es) Procedimiento para la fabricacion de derivados de tiadiazol activos sobre el sistema nervioso central
GB1437364A (en) Pesticidal phosphorus-containing triazole derivatives
CA2151096A1 (fr) Nouveaux derives tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pahrmaceutiques les contenant
AU557979B2 (en) Thiazolidin-and hydrothiazin-derivatives
ES8607251A1 (es) Procedimiento para la obtencion de derivados de iminometilazolilo
FR2351101A1 (fr) Pyrrolidones, leur procede de preparation et leurs applications therapeutiques
GB1321691A (en) Dihydro-3-piperidyl-2 3h-furanone derivatives

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303